Genmab ponders next steps after preliminary cancer candidate results

Biotech firm Genmab and partner Abbvie have reported topline results from a phase I/II study of candidate epcoritamab, a subcutaneous drug against large B-cell lymphoma (LBCL), the companies have announced in a joint press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab value drops by over USD 1.5bn after royalties defeat
For subscribers
Abbvie takes over Novo Holdings portfolio company
For subscribers